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Abstracts 
NO-38. A RETROSPECTIVE ANALYSIS OF THE EFFICACY AND 
TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH BRAIN 
TUMOR 
Marlon G. Saria1, Courtney Corle!, Jethro Hu2, Jeremy Rudnick2, 
Surasak Phuphanich2, Maciej M. Mrugala3, Laura K. Lee3, Beverly D. Fu4, 
Daniela A. Bota4, Ryan Y. Kimi, Tiffany Brown1, Homira Feely1, 
Alexander Hu 1, Jan Drappatzs, Patrick Y. Wens, Jon£ W. Lees, Bob Carter1, and Santosh Kesari1; 1UC San Diego, La Jolla, CA; Cedars-Sinai Medical 
Center, Los Angeles, CA; 3University of Washington, Seattle, WA; 4UC
Irvine, Irvine, CA; sBrigham and Women's Hospital, Boston, MA 
BACKGROUND: As many as 30% to 50% of brain tumor patients 
present with seizures, and many more remain at risk of developing seizures 
over the disease course. The management of seizures in these patients is com­
plicated by tumor growth and the numerous adverse effects and drug inter­
actions of traditional anti-epileptic drugs (AEDs), which are seen more 
frequently in patients with brain tumors than in the general epilepsy popu­
lation. To the best of our knowledge, there have been no published studies 
looking at the efficacy and tolerability of lacosamide in controlling seizures 
in patients with brain tumors. AIM: To determine the efficacy and tolerabil­
ity of lacosamide in patients with brain tumors. DESIGN: We performed a 
retrospective chart review of the medical records of all patients with a diag­
nosis of a primary brain tumor who were placed on lacosamide at 5 academic 
medical centers with tertiary brain tumor programs in the U.S. The main 
outcome measures were seizure frequency and toxicities. RESULTS: The 
majority of the patients had gliomas (95%). Fifty-five (79%) patients had 
partial seizures only, and 12 (17%) had generalized seizures. Most (74%) 
of the patients were started on lacosamide because of recurrent seizures. 
Forty-six patients (66%) reported a decrease in seizure frequency, and 21 
(30%) reported stable seizures. Most of the patients (n = 54, 77%) placed 
on lacosamide did not report any toxicities. DISCUSSION: Of the newer 
AEDs, lacosamide has not been evaluated in a population of patients with 
brain tumors. Our retrospective analysis demonstrated that lacosamide 
was both effective and well tolerated as an add-on AED in patients with 
brain tumors. Lacosamide's novel mechanism of action will allow for con­
current use with other AEDs as documented by its efficacy across many 
different types of AEDs used in our population. 
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